Literature DB >> 19276802

Albuminuria in children.

Erin R Rademacher1, Alan R Sinaiko.   

Abstract

PURPOSE OF REVIEW: Albuminuria is a marker of present and future cardiovascular and renal morbidity, and mortality, in adults. Because the roots of these diseases extend back into childhood, assessment of albuminuria has become relevant to child and adolescent clinical care. RECENT
FINDINGS: Normal levels of albumin excretion in children are well below the cut-off for microalbuminuria. In healthy children, albuminuria relates to fasting insulin, but not blood pressure, BMI, lipid levels, fasting glucose, or insulin resistance. In obese children, albuminuria relates to multiple measures of insulin resistance. In children with type 1 diabetes, hemoglobin A1c seems to be the most consistent clinical predictor of microalbuminuria although multiple mechanisms seem to be involved, including genetic polymorphisms. Children with type 2 diabetes and hypertension already exhibit microalbuminuria.
SUMMARY: When considering the population as a whole, children make ideal subjects in which to study the natural history of albuminuria given their relative lack of multiple morbidities commonly seen in adults. The unfortunate rise in 'adult' diseases in the pediatric age group makes this especially relevant. There is a need for longitudinal studies examining predictors of elevated urinary albumin levels as well as potential treatment strategies.

Entities:  

Mesh:

Year:  2009        PMID: 19276802     DOI: 10.1097/MNH.0b013e3283294b98

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  33 in total

1.  Chronic kidney disease and albuminuria in children with sickle cell disease.

Authors:  Marianne McPherson Yee; Shameem F Jabbar; Ifeyinwa Osunkwo; Lisa Clement; Peter A Lane; James R Eckman; Antonio Guasch
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

2.  Chapter 1: Definition and classification of CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01

3.  The population-based prevalence of albuminuria in children.

Authors:  Nicholas Larkins; Armando Teixeira-Pinto; Jonathan Craig
Journal:  Pediatr Nephrol       Date:  2017-07-27       Impact factor: 3.714

4.  Role of nitric oxide (NO) metabolism and inflammatory mediators in childhood obesity.

Authors:  András Hrabák; László Derzbach; Ildikó Csuka; Tamás Bajor; Anna Körner
Journal:  Inflamm Res       Date:  2011-08-27       Impact factor: 4.575

5.  Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms.

Authors:  Djalila Mekahli; Adrian S Woolf; Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2010-08-05       Impact factor: 3.714

6.  Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes.

Authors:  Ian B McKittrick; Yolanda Bogaert; Kristen Nadeau; Janet Snell-Bergeon; Amber Hull; Tao Jiang; Xiaoxin Wang; Moshe Levi; Karen S Moulton
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-14

Review 7.  Metabolic acidosis-induced insulin resistance and cardiovascular risk.

Authors:  Gema Souto; Cristóbal Donapetry; Jesús Calviño; Maria M Adeva
Journal:  Metab Syndr Relat Disord       Date:  2011-02-25       Impact factor: 1.894

8.  Obese children and adolescents have elevated nighttime blood pressure independent of insulin resistance and arterial stiffness.

Authors:  Kristian N Hvidt; Michael H Olsen; Jens-Christian Holm; Hans Ibsen
Journal:  Am J Hypertens       Date:  2014-04-09       Impact factor: 2.689

Review 9.  Evaluation of hypertension in children.

Authors:  Gaurav Kapur; Rossana Baracco
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

10.  Fetal and infant growth patterns and kidney function at school age.

Authors:  Hanneke Bakker; Romy Gaillard; Oscar H Franco; Albert Hofman; Albert J van der Heijden; Eric A P Steegers; H Rob Taal; Vincent W V Jaddoe
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.